Concepedia

Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study

Julia Brandts, Sarah Bray, Guillermo Villa, Alberico L. Catapano, Neil R Poulter, Antonio J. Vallejo‐Vaz, Kausik K. Ray

The Lancet Regional Health - Europe · 2023 · 35 citations · 26 references

DOIFull text

Open access

Abstract

Amgen.

References

26

2018 ESC/ESH Guidelines for the management of arterial hypertension

Bryan Williams, Giuseppe Mancia, Wilko Spiering et al. · European Heart Journal · 2018 · 10.1K citations · Full text

2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i>

François Mach, Colin Baigent, Alberico L. Catapano et al. · European Heart Journal · 2019 · 8.4K citations · Full text

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Frederick J. Raal, David Kallend, Kausik K. Ray et al. · New England Journal of Medicine · 2020 · 755 citations · Full text

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Evan A. Stein, Robert Dufour et al. · The Lancet · 2014 · 734 citations

, , +11

EU-Wi<i>d</i>e Cross-Section<i>a</i>l Obser<i>v</i>at<i>i</i>o<i>n</i>al Study of Lipid-Modifying Therapy Use in Se<i>c</i>ondary and Pr<i>i</i>mary Care: the DA VINCI study

Kausik K. Ray, Bart Molemans, W. Marieke Schoonen et al. · European Journal of Preventive Cardiology · 2020 · 699 citations · Full text